AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01807637 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stim (tDCS)
Description: During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
Study NCT01807637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stim (tDCS)
Description: During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
Study NCT01756937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imotun
Description: 300.03mg/cap,orally, 1 capsule once daily for 24 weeks
Study NCT01756937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule once daily for 24 weeks
Study NCT01255878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusal stabilization splint
Study NCT01255878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentine
Description: 100 mg(1 capsule)three times per day for two months
Study NCT02850770 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pedometers and Walking Logs
Description: Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
Study NCT02850770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometers and Walking Logs
Description: Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
Study NCT02850770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Messaging
Description: Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
Study NCT02850770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family/Friend Support
Description: Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
Study NCT03474510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local infiltration of liposomal bupivacaine
Description: Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
Study NCT03474510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of ropivacaine interscalene nerve block
Description: All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
Study NCT04320173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%
Description: Three patches are applied to the subject's back for 12 hours.
Study NCT04320173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Three patches are applied to the subject's back for 12 hours.
Study NCT04320173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine medicated plaster 5%
Description: Three plasters are applied to the subject's back for 12 hours.
Study NCT00821028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
Study NCT04328532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examination (45 min max) with potential oxygen delivery for 10 min
Study NCT04118478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-component phased training program
Description: The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
Study NCT01867723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet communication application
Description: Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
Study NCT00535808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroprusside
Description: Administration of nitroprusside
Study NCT00535808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerine
Description: Administration of nitroglycerine
Study NCT00535808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Administration of Sevoflurane
Study NCT02512978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Study NCT04029610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia with lidocaine and adrenalin.
Description: Local anesthesia with lidocaine and adrenalin.
Study NCT04029610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and adrenalin
Description: lidocaine and adrenalin
Study NCT04029610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and arterial blockage
Description: lidocaine and arterial blockage
Study NCT01565096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg BID
Study NCT01565096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg BID
Study NCT01565096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg twice daily
Study NCT01565096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride at individual dose
Study NCT00419770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: 20 mg/kg enterally per day
Study NCT00419770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00419770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal amphotericin B
Study NCT00419770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Study NCT01724502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and muscle biopsies
Description: Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
Study NCT00818337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
Study NCT01024439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transumbilical single incision laparoscopic appendicectomy
Description: Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done.
Study NCT01024439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic appendicectomy
Description: Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings.
Study NCT02522806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
Study NCT00005856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00005856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00473356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: receive amino acid supplement
Description: Receive amino acid supplement
Study NCT02973893 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02973893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VF001-DP LD
Description: VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
Study NCT02973893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VF001-DP HD
Description: VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
Study NCT04281992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUP1602-C
Description: AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
Study NCT02812732 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DOSE HPV
Description: The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3\&4. Action Plans are developed in Session 5. Sessions 6\&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles.
Study NCT02328443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02328443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Study NCT02328443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Study NCT03257085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat
Description: Participants following low-carbohydrate, high-fat diet for 8 weeks.
Study NCT03257085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, moderate-fat
Description: Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
Study NCT04066166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Palpation
Description: All healthy subjects palpated
Study NCT03587649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1126
Description: Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures.
Study NCT03905486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300mg
Description: Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
Study NCT03905486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined pregabalin 300mg and milancipran 100mg
Description: Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
Study NCT02702817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: pale blue oval tablets
Study NCT02702817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
Study NCT03663803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief theory-based health promotion intervention (group-based)
Description: The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
Study NCT01578694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
Study NCT03299907 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Study NCT02219945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
Study NCT01355081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study NCT01355081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo
Study NCT02193178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A Toric
Description: Contact lenses
Study NCT01122147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chamomilla tincture mouthwash
Description: The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
Study NCT01122147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash
Description: The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
Study NCT05083299 — intervention group
Intervention type: DRUG
Intervention: Sarpogrelate
Description: Anpl-one SR
Study NCT02328690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Technology
Description: A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
Study NCT02328690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Binaural Beat Technology
Description: A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
Study NCT02011204 — intervention group
Intervention type: DEVICE
Intervention: Electrical impedance myography (EIM)
Description: In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.
Study NCT02344992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT02344992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT00653471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcapmicro-stream device with Smart CapnoLine Plus
Description: nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
Study NCT00653471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcap micro-stream device with CapnoLine
Description: CO2 measured via nasal cannula
Study NCT00653471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).
Description: CO2 measured via nasal cannula
Study NCT00948519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser + ICG
Description: ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
Study NCT00948519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser only
Description: same only without ICG
Study NCT04250051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04250051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT04250051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04250051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04250051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study NCT02268500 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza vaccine